Mortality among Cancer Patients within 90 Days of Therapy in a Tertiary Hospital, Tanzania: Is Our Pretherapy Screening Effective?

Table 2

Baseline characteristics for patients who died within 90 days.

Variable	Patient identification
	1	2	3	4	5	6	7	8	9	10	11	12
Age (years)	76	71	52	43	65	50	49	62	51	51	52	33
BMI (kg/m^2)	18	29	22.2	25	21	25	27.7	23.2	25.2	22.8	24.8	20.8
Cancer type	Nasopharyngeal cancer	Breast cancer	GIT metastatic cancer	Malignant melanoma	Cervical cancer	Pancreatic cancer	Sinonasal cancer	Adenocarcinoma of the nose	Cervical cancer	Cervical cancer	Lung cancer	Squamous cell carcinoma of the cheek
Type of therapy
Type 1; Type 2; Type 3	5-Fluorouracil; Cisplatin; Paclitaxel	Carboplatin	Docetaxel; Dexamethasone	Carboplatin	Cisplatin; Dacarbazine	Gemcitabine; 5-Fluorouracil	Cisplatin; Radiotherapy	Cisplatin	Cisplatin; Radiotherapy	Cisplatin; 5-Fluorouracil	Docetaxel; Dexamethasone	Cisplatin; 5-Fluorouracil; Dexamethasone
Stage of cancer	3	4	4	3	3	3	4	4	2	3	3	3
Baseline neutrophil (×10^9/L)	3.51	19.7	3.2	2.38	2.94	5.65	0.75	2.83	5.79	3.21	3.05	1.47
Neutrophil 1 (×10^9/L)	2.9	19.8	2.87	3.92	1.09	5.17	1.65	2.6	5.8	2.25	2.4	1.2
Neutrophil 2 (×10^9/L)	—	—	1.35	2.41	1.08	—	1.41	1.6	7.46	—	1.3	1.7
Neutrophil 3 (×10^9/L)	—	—	—	1.13	—	—	—	3.17	2.69	—	—	—
Neutrophil 4 (×10^9/L)	—	—	—	—	—	—	—	3.07	3.91	—	—	—
Neutrophil 5 (×10^9/L)	—	—	—	—	—	—	—	1	—	—	—	—
Baseline Hb (g/dL)	9.6	11.1	11	9.9	10.1	9	9.1	10.5	7.3	10.3	11.4	9.5
Baseline WBC (×10^9/L)	6.14	4.58	4.8	4.29	5.33	8.37	2.92	4.8	8.84	5.1	4.97	2.29
Karnofsky score (%)	80	20	60	80	90	70	90	70	80	90	80	70
Blood culture	No growth	No growth	No growth	No growth	No growth	No growth	No growth	No growth	No growth	No growth	S. aureus	No growth
Urine culture	No growth	P. aeruginosa	No growth	No growth	No growth	No growth	No growth	No growth	No growth	No growth	No growth	E. coli
Body temperature(°C)	36	38.2	37.1	36.3	36.8	37.2	37	35.2	35.5	36.7	35.3	36.8